Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Oncology Practice

• Publication date

  2017-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JOP.2016.020347PMID 28282278PMCID PMC5456257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

  2017cited by this paper
• Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer

  2016cited by this paper
• IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

  2016cited by this paper
• Overcoming Therapeutic Resistance by Targeting Cancer Inflammation.

  2016cited by this paper
• Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.

  2016cited by this paper
• The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer

  2016cited by this paper
• Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

  2016cited by this paper
• Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

  2016cited by this paper
• Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma

  2016cited by this paper
• Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study.

  2016cited by this paper
• Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

  2016cited by this paper
• Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

  2016cited by this paper
• IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

  2016cited by this paper
• Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

  2016cited by this paper
• Durable antitumor responses to CD47 blockade require adaptive immune stimulation

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

  2015cited by this paper
• JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.

  2015cited by this paper
• Inflammation and cancer: advances and new agents

  2015cited by this paper
• Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

  2015cited by this paper
• CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

  2015cited by this paper
• Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

  2015cited by this paper
• Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

  2015cited by this paper
• Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

  2014cited by this paper
• Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

  2014cited by this paper
• Harnessing the antitumor potential of macrophages for cancer immunotherapy

  2013cited by this paper
• The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

  2013cited by this paper
• Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

  2012cited by this paper
• Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy

  2012cited by this paper
• Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

  2012cited by this paper
• Cancer classification using the Immunoscore: a worldwide task force

  2012cited by this paper
• The immune contexture in human tumours: impact on clinical outcome

  2012cited by this paper
• Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF

  2012cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Programmed cell removal: a new obstacle in the road to developing cancer

  2011cited by this paper
• Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

  2011cited by this paper
• Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer

  2011cited by this paper
• PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.

  2011cited by this paper
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

  2011cited by this paper
• Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

  2011cited by this paper
• Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

  2011cited by this paper
• Macrophage diversity enhances tumor progression and metastasis.

  2010cited by this paper
• Dual roles for immunity in gastrointestinal cancers.

  2010cited by this paper
• Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

  2009cited by this paper
• STATs in cancer inflammation and immunity: a leading role for STAT3

  2009cited by this paper
• Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis

  2008cited by this paper
• Cytokines and their relationship to the symptoms and outcome of cancer

  2008cited by this paper
• Celecoxib for the prevention of colorectal adenomatous polyps.

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

  2003cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Aspirin use and reduced risk of fatal colon cancer.

  1991cited by this paper

• Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer.

  2026cites this paper
• Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer.

  2024cites this paper
• Interleukin-1 Receptor-Associated Kinase 1 in Cancer Metastasis and Therapeutic Resistance: Mechanistic Insights and Translational Advances

  2024cites this paper
• Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins

  2024cites this paper
• Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

  2024cites this paper
• Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration.

  2023cites this paper
• What Exactly Is Inflammation (and What Is It Not?)

  2022cites this paper
• Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy.

  2022cites this paper
• Changes in Patient-Reported Health Status in Advanced Cancer Patients from a Symptom Management Clinic: A Longitudinal Study Conducted in China

  2022cites this paper
• Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer

  2021cites this paper
• A new hypothesis to explain skin cancer risk in kidney allograft recipients

  2021cites this paper
• Monitoring and Modulating Inflammation-Associated Alterations in Synaptic Plasticity: Role of Brain Stimulation and the Blood–Brain Interface

  2021cites this paper
• Inflammatory and Immunogenic Response of the Tissue after Application of Freeze-Dried Hydroxyapatite Gypsum Puger Scaffold Compared to Freeze-dried Hydroxyapatite Bovine Scaffold

  2020cites this paper
• Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

  2020cites this paper
• The Skeletal Muscle as an Active Player Against Cancer Cachexia

  2019cites this paper
• Contribution of the Gut and Vaginal Microbiomes to Gynecological Cancers

  2019cites this paper
• Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

  2019cites this paper
• Preventive Oncology for the Gynecologist

  2019cites this paper
• Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy.

  2017cites this paper
• Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

  2017influential citation